Drugs V




Crenezumab

This drug entry is a **stub** and has not been fully annotated. It is scheduled to be annotated soon.

DENTIFICATION			
Name	Crenezumab		
Accession Number	DB11959		
Туре	Biotech		
Groups	Investigational		
Biologic Classification	Protein Based Therapies Monoclonal antibody (mAb)		
Description	Crenezumab has been used in trials	studying the treatment of Alzheime	r's Disease.
Protein chemical formula	Not Available		
Protein average weight	Not Available		
Sequences	Not Available		
Synonyms	Not Available		
External IDs ①	MABT5102A		
Categories	Alzheimer Disease, drug therapy Amino Acids, Peptides, and Proteins Antibodies	Blood Proteins Globulins Immunoglobulins	Immunoproteins Proteins Serum Globulins
UNII	<u>08AS5277H0</u>		
CAS number	1095207-05-8		
HARMACOLOGY			
Indication	Not Available		
Pharmacodynamics	Not Available		
Mechanism of action	Not Available		
Absorption	Not Available		

https://www.drugbank.ca/drugs/DB11959

Not Available



INTERACTIONS

Effects/ADRs ①

Drug Interactions

()

<u>ALL DRUGS</u> <u>APPROVED</u> <u>VET APPROVED</u> <u>NUTRACEUTICAL</u> <u>ILLICIT</u> <u>WITHDRAWN</u>

<u>INVESTIGATIONAL</u> <u>EXPERIMENTAL</u>

Show	10	entries	Search
DRUG	↑	INTERACTION	$\uparrow \downarrow$
<u>Abcixi</u>	imab	The risk or severity of adverse effects can be increased when Abciximab is of Crenezumab.	combined with
<u>Abituz</u>	<u>zumab</u>	The risk or severity of adverse effects can be increased when Crenezumab i Abituzumab.	s combined with
Adalin	<u>numab</u>	The risk or severity of adverse effects can be increased when Adalimumab i Crenezumab.	s combined with
Adeca	<u>itumumab</u>	The risk or severity of adverse effects can be increased when Adecatumuma Crenezumab.	ab is combined with
Aduca	<u>anumab</u>	The risk or severity of adverse effects can be increased when Crenezumab i Aducanumab.	s combined with
Afelim	<u>nomab</u>	The risk or severity of adverse effects can be increased when Afelimomab is Crenezumab.	s combined with
Alemt	<u>:uzumab</u>	The risk or severity of adverse effects can be increased when Alemtuzumab Crenezumab.	is combined with
Aliroc	<u>umab</u>	The risk or severity of adverse effects can be increased when Alirocumab is Crenezumab.	combined with
<u>Amatı</u>	<u>uximab</u>	The risk or severity of adverse effects can be increased when Crenezumab i Amatuximab.	s combined with
AMG 1	108	The risk or severity of adverse effects can be increased when AMG 108 is concerned to the control of the contro	ombined with

Showing 1 to 10 of 244 entries

2/4

Food Interactions

Not Available

General References Not Available



Clinical Trials (1)

Search Show 10 entries

PHASE ↑↓	STATUS ↑↓	PURPOSE ↑↓	${\color{red}CONDITIONS}\qquad \qquad {\color{blue}\uparrow}{\color{blue}\downarrow}$	COUNT ↑↓
1	Completed	Treatment	<u>Healthy Volunteers</u>	2
2	Active Not Recruiting	Treatment	Alzheimer's Disease (AD)	1
2	Completed	Treatment	<u>Alzheimer's Disease (AD)</u>	<u>3</u>
3	Active Not Recruiting	Treatment	<u>Alzheimer's Disease (AD)</u>	1
3	Recruiting	Treatment	Alzheimer's Disease (AD)	2

Showing 1 to 5 of 5 entries

<u><</u> 1 ≥

PHARMACOECONOMICS

Manufacturers	Not Available
Packagers	Not Available
Dosage forms	Not Available
Prices	Not Available
Patents	Not Available

PROPERTIES

State	Not Available
Experimental	Not Available

Properties

TAXONOMY

Description	Not Available
Kingdom	Organic Compounds
Super Class	Organic Acids
Class	Carboxylic Acids and Derivatives
Sub Class	Amino Acids, Peptides, and Analogues
Direct Parent	Peptides
Alternative Parents	Not Available
Substituents	Not Available

Molecular

1/9/2019

Crenezumab - DrugBank

Framework

Not Available

Drugs

Drug created on October 20, 2016 15:05 / Updated on November 02, 2018 07:18



About

About DrugBank

<u>DrugBank Blog</u>

Wishart Research Group

Terms of Use

<u>Privacy Policy</u>

Support


<u>FAQ</u>

<u>Help</u>

Email Support







This project is supported APM to Canadian Institutes of Health Research (award #111062), Alberta Innovates - Health Solutions, and by The Metabolomics Innovation Centre (TMIC), a nationally-funded research and core facility that supports or twide range of cutting-edge metabolomic studies. TMIC is funded by **Genome Alberta**, **Genome <u>British Columbia</u>**, and **<u>Genome Canada</u>**, a not-for-profit organization that is leading Canada's national genomics strategy with funding from the federal government. Maintenance, support, and commercial licensing is provided by **OMx Personal Health Analytics, Inc.** Designed by **Educe** Design & Innovation Inc.









GenomeBritishColumbia

Genome Canada